Regeneron drug shows muscle preservation in GLP-1 weight loss trial

October 1, 2026 11:30 AM

Regeneron Pharmaceuticals (NASDAQ: REGN) announced results from its Phase 2 COURAGE trial showing that trevogrumab, an anti-myostatin antibody, preserved lean ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found